Ten-day Decitabine with Venetoclax in Acute Myeloid Leukemia: A Single-arm Phase 2 Trial

BACKGROUND: Venetoclax with hypomethylating agents is a new standard of care for newly diagnosed (ND) patients with acute myeloid leukemia (AML) who are 75 years or older, or unfit for intensive chemotherapy. Pharmacodynamic studies have suggested superiority of the longer 10-day regimen of decitabi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Lancet Haematol
Autores principales: DiNardo, Courtney D., Maiti, Abhishek, Rausch, Caitlin R., Pemmaraju, Naveen, Naqvi, Kiran, Daver, Naval G., Kadia, Tapan M., Borthakur, Gautam, Ohanian, Maro, Alvarado, Yesid, Issa, Ghayas C., Montalban-Bravo, Guillermo, Short, Nicholas J., Yilmaz, Musa, Bose, Prithviraj, Jabbour, Elias J., Takahashi, Koichi, Burger, Jan, Garcia-Manero, Guillermo, Jain, Nitin, Kornblau, Steven M., Thompson, Philip A., Estrov, Zeev, Masarova, Lucia, Sasaki, Koji, Verstovsek, Srdan, Ferrajoli, Alessandra, Weirda, William G., Wang, Sa A., Konopleva, Sergej, Chen, Zhining, Pierce, Sherry A., Ning, Jing, Qia, Wei, Ravandi, Farhad, Andreeff, Michael, Welch, John S., Kantarjian, Hagop M., Konopleva, Marina Y.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7549397/
https://ncbi.nlm.nih.gov/pubmed/32896301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(20)30210-6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares